US Patent Issued to Amgen on Sept. 22 for "RNAi constructs and methods for inhibiting LPA expression" (California Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,742,169, issued on Sept. 22, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"RNAi constructs and methods for inhibiting LPA expression" was invented by Bin Wu (Thousand Oaks, Calif.), Michael Ollmann (San Carlos, Calif.), Oliver Homann (Berkeley, Calif.) and Yuan Cheng (Newbury Park, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, st...